Scholarlink

Background <p>Small cell lung cancer (SCLC) is a high-grade and aggressive neuroendocrine carcinoma that remains incurable due to the emergence of drug resistance and frequent relapse. This study aimed to clarify the therapeutic potential and detailed mechanism of altretamine against SCLC.</p> Methods <p>Altretamine-triggered cytotoxicity and lipid peroxidation were determined by EdU, FerroOrange probes, etc. GPX4 promoter methylation was evaluated by Methylation-specific PCR, chromatin immunoprecipitation, etc. Altretamine-induced GPX4 degradation was examined by bio-layer interferometry, immunoprecipitation, etc.</p> Results <p>Altretamine mainly initiates ferroptosis in SCLC cells, accompanied by accumulation of intracellular ROS and lipid peroxidation. Mechanistically, altretamine facilitated the binding of DNMT3A to GPX4 promoter, leading to DNA methylation of GPX4 gene and subsequent transcriptional repression. Moreover, altretamine directly bound to GPX4 protein and accelerated the lysosomal degradation of GPX4 protein in a HSC70-dependent manner. Inhibition of DNA demethylation by inactivating Ten-eleven translocation (TET) proteins synergistically strengthened the anti-SCLC activity of altretamine.</p> Conclusions <p>Our findings revealed the first time that altretamine induced ferroptotic cell death by promoting DNMT3A-mediated epigenetic silencing of GPX4 gene and HSC70-mediated lysosomal degradation of GPX4 protein in SCLC cells. Altretamine alone or in combination with TET inhibitors is a valuable and credible strategy for the clinical treatment of SCLC.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4

  • 期刊论文

  • 发表日期：

    2026年7月2日

查看全文
  • Qin Li,
  • Hang Yuan,
  • Liang Li,
  • Gang Zhao,
  • Kai Liu,
  • Siqi Li,
  • Shan Li,
  • Minghui Zhao,
  • Qiming Kou,
  • Qijing Wang,
  • Guanru Wang,
  • Huayang Yu,
  • Kang Chen,
  • Jie Qu,
  • Hongbai Chen,
  • Chenghong Lu,
  • Shiyu Sun,
  • Lin Ping,
  • Kai Li

摘要

Background

Small cell lung cancer (SCLC) is a high-grade and aggressive neuroendocrine carcinoma that remains incurable due to the emergence of drug resistance and frequent relapse. This study aimed to clarify the therapeutic potential and detailed mechanism of altretamine against SCLC.

Methods

Altretamine-triggered cytotoxicity and lipid peroxidation were determined by EdU, FerroOrange probes, etc. GPX4 promoter methylation was evaluated by Methylation-specific PCR, chromatin immunoprecipitation, etc. Altretamine-induced GPX4 degradation was examined by bio-layer interferometry, immunoprecipitation, etc.

Results

Altretamine mainly initiates ferroptosis in SCLC cells, accompanied by accumulation of intracellular ROS and lipid peroxidation. Mechanistically, altretamine facilitated the binding of DNMT3A to GPX4 promoter, leading to DNA methylation of GPX4 gene and subsequent transcriptional repression. Moreover, altretamine directly bound to GPX4 protein and accelerated the lysosomal degradation of GPX4 protein in a HSC70-dependent manner. Inhibition of DNA demethylation by inactivating Ten-eleven translocation (TET) proteins synergistically strengthened the anti-SCLC activity of altretamine.

Conclusions

Our findings revealed the first time that altretamine induced ferroptotic cell death by promoting DNMT3A-mediated epigenetic silencing of GPX4 gene and HSC70-mediated lysosomal degradation of GPX4 protein in SCLC cells. Altretamine alone or in combination with TET inhibitors is a valuable and credible strategy for the clinical treatment of SCLC.